• Proceedings of the Korean Society of Medical Physics Conference
• /
• 1999.11a
• /
• pp.79-79
• /
• 1999

• Korean Journal of Radiology
• /
• v.22 no.7
• /
• pp.1087-1099
• /
• 2021

MRI has become important for the detection of prostate cancer. MRI-guided biopsy is superior to conventional systematic biopsy in patients suspected with prostate cancer. MRI is also increasingly used for monitoring patients with low-risk prostate cancer during active surveillance. It improves patient selection for active surveillance at diagnosis, although its role during follow-up is unclear. We aim to review existing evidence and propose a practical approach for incorporating MRI into active surveillance protocols.

• Progress in Medical Physics
• /
• v.1 no.1
• /
• pp.11-21
• /
• 1990

No Abstract, See Full Text

• The Korean Journal of Pain
• /
• v.1 no.1
• /
• pp.1-2
• /
• 1988

• Proceedings of the Microbiological Society of Korea Conference
• /
• 1998.04a
• /
• pp.63.2-63.2
• /
• 1998

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.3
• /
• pp.1905-1909
• /
• 2013

Objective: The aim of the current study was to evaluate changes in treatment outcomes in terms of health-related quality of life (HRQoL) and symptom burden at zero, one, three, and six months after an initial diagnosis of colorectal cancer. The demographic and clinical characteristics that account for outcome changes in patients were investigated using a repeated measures framework. Methods and Materials: A cohort study was performed of 134 colorectal cancer patients followed from diagnosis to 6 months post-treatment in Central Taiwan. HRQoL and symptoms were assessed at diagnosis and one, three, and six months thereafter. The Functional Assessment of Cancer Therapy-Colon (FACT-C) questionnaire, VAS pain, and the Memorial Symptom Assessment Scale (MSAS) were used for data collection. A generalized estimating equation (GEE) was applied for statistical analysis. Results: The majority of the patients were male (55%) and married (91.5%). The mean age was 60.4 years (SD = 11.71). Most were diagnosed stage III and IV colorectal cancer (54.5%). All underwent surgery; some also received chemotherapy (CT) or concurrent chemoradiation therapy (CCRT). The results of the GEE showed that overall, the HRQoL, pain, and symptoms of the patients significantly improved over the treatment period. Patients with stage IV disease who had received surgery and CCRT showed the worst HRQoL. Females, patients with comorbidity, and stage IV patients had higher pain scores over time. Female and stage IV patients had more severe physical symptoms, whereas stage II and IV patients had worse psychological symptoms over time. Conclusion: The patients' HRQoL, pain, and symptoms significantly improved over the 6-month treatment period. Certain patient and clinical variables accounted for changes in treatment outcomes regarding HRQoL and symptom burden in colorectal cancer patients.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.3
• /
• pp.1981-1984
• /
• 2013

Objective: The optimal duration of adjuvant trastuzumab treatment in patients with HER2-positive breast cancer is not known. The aim of this study was to evaluate the efficacy of 6 months of adjuvant trastuzumab treatment in patients with stage II or III HER2-positive breast cancer. Methods: The records of patients with HER2-positive stage II or III breast cancer who were admitted to the Breast Center of Taipei Medical University Hospital and Yuan's General Hospital between 2000 and 2008 were reviewed. All patients received adjuvant trastuzumab at an initial dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg/week for 22 weeks in combination with chemotherapy. Results: A total of 51 patients were included with a mean age of 46.9 years. Approximately 55% of the patients had stage III disease. The mean follow-up time from initiation of treatment was 45.2 months (range, 0.9 to 85 months). During follow-up, 46 patients (90.2%) did not experience tumor recurrence. The mean estimated disease free survival was 80.2 months. The estimated 1-, 2-, 5-, and 7-year survival rates were 97.9%, 93.1%, 93.1%, and 93.1%, respectively. The most common adverse effects were gastrointestinal symptoms (21.6%), chills (17.6%), dizziness (9.8%), and bone pain (7.8%). No cardiac or hematologic adverse events occurred. Conclusion: Adjuvant therapy with trastuzumab for 6 months resulted in a clinical benefit in patients with HER2-positive breast cancer.

• Journal of Plant Biotechnology
• /
• v.47 no.4
• /
• pp.273-282
• /
• 2020

In Vietnam, Celastrus hindsii Benth, a medicinal plant rich in secondary metabolites, has been used to alleviate distress caused by ulcers, tumors, and inflammation for generations. The occurrence of two phenotypes, Broad Leaf (BL) and Narrow Leaf (NL), has raised questions about the selection of appropriate varieties for conservation and crop improvement to enhance medicinal properties. This study examined molecular differences in C. hindsii by comparing protein profiles between the NL and BL types using 2D-PAGE and MS. Peptide sequences and proteins were identified by matching MS data against the MSPnr100 databases and verified using the MultiIdent tool on ExPASy and the Blast2GO software. Our results revealed notable variations in protein abundance between the NL and BL proteomes. Selected proteins were confidently identified from 12 protein spots, thereby highlighting the molecular variation between NL and BL proteomes. Upregulated proteins in BL were found to be associated with flavonoid and amino acid biosynthesis as well as nuclease metabolism, which probably attributed to the intraspecific variations. Several bioactive proteins identified in this study can have applications in cancer therapeutics. Therefore, the BL phenotype characterized by healthier external morphological features has higher levels of bioactive compounds and could be better suited for medicinal use.

• The Korean Journal of Pain
• /
• v.5 no.1
• /
• pp.17-22
• /
• 1992

Splanchnic nerve block(SNP) is performed to relieve intractable upper abdominal cancer pain. Boas, in a technique using fluoroscopy, was the first to note the difference between transcrural celiac plexus block and retrocrural splanchnic nerve block(SNB). We have experienced 10 cases of SNB at the T12 level under control of fluoroscopy. Our results support this approach as an effective method for upper abdominal cancer pain control.

• The Korean Journal of Pain
• /
• v.3 no.2
• /
• pp.172-176
• /
• 1990

In Incheon Severance Hospital, a secondary delivery hospital, anesthesiologists have treated cancer pain in the operation room when referred from other department. Intrathecal neurolytic block is a valuable means of producing high quality pain relief in any hospital. It is simple to carry out, requires brief hospitalization, can be used in elderly or severely ill patients, can be repeated with the block wears off and its duration is sufficient for the terminal cancer patients. We reviewed the clinical charateristics of the intrathecal alcohol and phenol-glycerine used in two cases of cancer with pain.